A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression

Andy Wijaya; Yi Wang; Dan Tang; Yuan Zhong; Boyan Liu; Meng Yan; Quhui Jiu; Wei Wu; Guixue Wang

doi:10.1039/D1TB01455B

A study of lovastatin and l-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression†

Andy Wijaya,

^a Yi Wang,^b Dan Tang,^a Yuan Zhong,^a Boyan Liu,^a Meng Yan,^a Quhui Jiu,^a Wei Wu

*^a and Guixue Wang

*^a

Author affiliations

* Corresponding authors

^a Key Laboratory for Biorheological Science and Technology of Ministry of Education State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing 400030, China
E-mail: david2015@cqu.edu.cn, wanggx@cqu.edu.cn

^b College of Basic Medical Sciences, Chongqing Medical University, Chongqing 400016, China

Abstract

Nitric oxide (NO) is an exceptional endogenous biological gas that mediates and regulates physiological and pathological processes in the human body. However, its synthesis process is impaired during athero-progression and formation. Hence, a strategy to boost NO production and target endothelial nitric oxide synthase (eNOS) is crucial and intriguing in atherosclerosis (AS) management. Herein, we prepare L-arginine (LA) and lovastatin (LV) co-loaded PLGA nanomedicine to achieve sustainable release for enhancing NO production. The utilization of LA reveals that LA has dual contributions, acting as a NO donor and enhancing the solubility of LV by stabilizing PLGA NPs. PLGA-LA/LV demonstrated its potential to boost NO in vitro and in vivo confirmed using DAF-FM DA, augment eNOS and p-eNOS mRNA and protein levels, and suppress the ki67 proliferation marker in VSMCs; in addition, it lowers the total cholesterol level of blood plasma in C57BL/6 mice. Moreover, PLGA can protect the compound delivered and enhance the bioavailability to reach and get released in the blood circulation after oral administration. Collectively, our results endow a safe and efficient nanomedicine outcome, specifically with potential for AS management.

Supplementary files

Article information

DOI: https://doi.org/10.1039/D1TB01455B
Article type: Paper
Submitted: 30 Jun 2021
Accepted: 14 Dec 2021
First published: 27 Dec 2021

Download Citation

J. Mater. Chem. B, 2022,10, 607-624

Permissions

Request permissions

A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression

A. Wijaya, Y. Wang, D. Tang, Y. Zhong, B. Liu, M. Yan, Q. Jiu, W. Wu and G. Wang, J. Mater. Chem. B, 2022, 10, 607 DOI: 10.1039/D1TB01455B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Journal of Materials Chemistry B

A study of lovastatin and l-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression†

Abstract

Supplementary files

Article information

Download Citation

Permissions

A study of lovastatin and L-arginine co-loaded PLGA nanomedicine for enhancing nitric oxide production and eNOS expression

Social activity

Search articles by author

Spotlight

Advertisements